---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-200535"
form_type: "8-K"
ticker: "MDXG"
cik: "0001376339"
company_name: "MIMEDX GROUP, INC."
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T17:31:17.836752+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MiMedx Q2 net sales $81.3M (+21.5% YoY); raises FY2023 growth guidance to mid-to-high teens

## Summary
- Net sales $81.3M (+21.5% YoY); net income $1.2M; Adj. EBITDA $14.1M (17.4% of sales).
- Raises full-year 2023 net sales growth guidance to mid-to-high teens.
- Appoints Doug Rice as CFO, rounding out executive team.
- Reports favorable appellate ruling affirming dismissal of securities class action.
- Announced strategic realignment focusing on Wound & Surgical businesses to improve profitability.

## SEC filing metadata
- accession: 0001193125-23-200535
- form_type: 8-K
- ticker: MDXG
- cik: 0001376339
- company_name: MIMEDX GROUP, INC.
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1376339/000119312523200535/0001193125-23-200535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1376339/000119312523200535/d472149d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-200535
- JSON: https://secwatch.observer/filing/0001193125-23-200535.json
- Plain text: https://secwatch.observer/filing/0001193125-23-200535.txt

## Key facts
- Earnings Releases
  MIMEDX GROUP, INC. reported second quarter ended June 30, 2023 results: revenue $81.3 million, net income $1.2 million. Guidance raised.
  - Period: second quarter ended June 30, 2023
  - Revenue: $81.3 million
  - Net income: $1.2 million
  - Guidance: raised
  - Result: reported results
  source text: report on Form 8-K. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 MIMEDX Announces Second Quarter 2023 Operating and Financial Results Records Second Quarter Net Sales of $81.3 Million; an Increase of 21.5% Over the Prior Year Period Increases Full-Year 2023 Guidance for Net Sales Growth Welcomes Highly Successful MedTech Executive as Chief Financial Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1376339/000119312523200535/0001193125-23-200535-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.